NTP-CERHR expert panel report on the reproductive and developmental toxicity of fluoxetine

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 71, Issue 4, 2004, Pages 193-280

  Hines, Ronald N ^a   Adams, Jane ^b   Buck, Germaine M ^c   Faber, Willem ^d   Holson, Joseph F ^e   Jacobson, Sandra W ^f   Keszler, Martin ^g   McMartin, Kenneth ^h   Segraves, Robert Taylor ⁱ   Singer, Lynn T ^j   Sipes, I Glenn ^k   Williams, Paige L ^l   Scialli, Anthony R ^m  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d WFT Consulting   (United States)

^e WIL RESEARCH LABORATORIES   (United States)

^f WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^h LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

ⁱ METROHEALTH MEDICAL CENTER   (United States)

^j CASE WESTERN RESERVE UNIVERSITY   (United States)

^k UNIVERSITY OF ARIZONA   (United States)

^l HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^m Sciences International Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; FLUOXETINE; MONOAMINE OXIDASE INHIBITOR; NORFLUOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGGRESSION; AGITATION; AKATHISIA; ANOREXIA; ANXIETY DISORDER; APATHY; AREA UNDER THE CURVE; ARTHRALGIA; BIRTH DEFECT; BIRTH WEIGHT; BLEEDING; BULIMIA; CHILD GROWTH; CLINICAL TRIAL; CONFUSION; CONGENITAL MALFORMATION; DEVELOPMENTAL DISORDER; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG USE; DYSPEPSIA; DYSTHYMIA; EDEMA; FEVER; GENOTOXICITY; GESTATIONAL AGE; HUMAN; HYPERBILIRUBINEMIA; HYPERREFLEXIA; HYPOGLYCEMIA; HYPOMANIA; HYPOTHERMIA; INSOMNIA; IRRITABILITY; JAUNDICE; LETHARGY; LYMPHADENOPATHY; MAJOR DEPRESSION; MANIA; MAXIMUM PERMISSIBLE DOSE; META ANALYSIS; MYOCLONUS; NAUSEA; NERVOUSNESS; OBSESSIVE COMPULSIVE DISORDER; PANIC; PREMATURITY; PREMENSTRUAL DYSPHORIC DISORDER; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RASH; REPRODUCTIVE TOXICITY; RESPIRATORY DISTRESS; REVIEW; SEROTONIN SYNDROME; SERUM SICKNESS; SEXUAL DYSFUNCTION; SHIVERING; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; SYSTEMATIC REVIEW; TABLET; TACHYPNEA; THROMBOCYTOPENIA; TREMOR; URTICARIA;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; FLUOXETINE; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; REPRODUCTION;

EID: 4444349259     PISSN: 15429733     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdrb.20014     Document Type: Review

References (240)

1. American Academy of Pediatrics. 1994a. AAP issues policy statement on the transfer of drugs and other chemicals into human milk. Am Fam Physician 49:1527-1529.
2. American Academy of Pediatrics. 1994b. The transfer of drugs and other chemicals into human milk. Pediatrics 93:137-150.
3. Abdul M, Logothetis CJ, Hoosein NM. 1995. Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol 154:247-250.
4. Abebe-Campino G, Offer D, Stahl B, Merlob P. 2002. Cardiac arrhythmia in a newborn infant associated with fluoxetine use during pregnancy. Ann Pharmacother 36:533-534.
5. Addis A, Koren G. 2000. Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psychol Med 30:89-94.
6. Alderman CP, Moritz CK, Ben-Tovim DI. 1992. Abnormal platelet aggregation associated with fluoxetine therapy. Ann Pharmacother 26:1517-1519.
7. Alderman CP, Seshadri P, Ben Tovim DI. 1996. Effects of serotonin reuptake inhibitors on hemostasis. Ann Pharmacother 30:1232-1234.
8. Alfaro CL, Lam YW, Simpson J, Ereshefsky L. 1999. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol 19:155-163.
9. Alfaro CL, Lam YW, Simpson J, Ereshefsky L. 2000. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol 40:58-66.
10. Altamura AC, Moro AR, Percudani M. 1994. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 26:201-214.
11. Angst J. 1998. Sexual problems in healthy and depressed patients. Int Clin Psychopharmacol 13(Suppl):S1-3.
12. Armitage R, Emslie G, Rintelmann J. 1997. The effect of fluoxetine on sleep EEG in childhood depression: a preliminary report. Neuropsychopharmacology 17:241-245.
13. Arya DK, Taylor WS. 1995. Lactation associated with fluoxetine treatment. Aust N Z J Psychiatry 29:697.
14. Ashton A, Hamer R, Rosen R. 1997. Serotonin reuptake inhibitor-induced sexual dysfunction and its treatment: a large scale retrospective study of 596 outpatients. J Sex Marital Ther 23:165-176.
15. Baldwin D. 2001. Depression and sexual dysfunction. Br Med Bull 57:81-99.
16. Balon R, Yeragani VK, Pohl R, Ramesh C. 1993. Sexual Dysfunction During Antidepressant Treatment. J Clin Psychiatry 54:209-212.
17. Bastos EF, Marceline JL, Amaral AR, Serfaty CA. 1999. Fluoxetine-induced plasticity in the rodent visual system. Brain Res 824:28-35.
18. Baum AL, Misri S. 1996. Selective serotonin-reuptake inhibitors in pregnancy and lactation. Harv Rev Psychiatry 4:117-125.
19. Benazzi F, Mazzoli M. 1994. Fluoxetine-induced sexual dysfunction: a dose-dependent effect? Pharmacopsychiatry 27:246.
20. Bendele RA, Adams ER, Hoffman WP, Gries CL, Morton DM. 1992. Carcinogenicity studies of fluoxetine hydrochloride in rats and mice. Cancer Res 52:6931-6935.
21. Bertilsson L, Dahl ML, Tybring G. 1997. Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand Suppl 391:14-21.
22. Birmaher B, Axelson DA, Monk K, Kalas C, Clark DB, Ehmann M, Bridge J, Heo J, Brent DA. 2003. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 42:415-423.
23. Birmaher B, Waterman GS, Ryan N, Cully M, Balach L, Ingram J, Brodsky M. 1994. Fluoxetine for childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 33:993-999.
24. Bolo NR, Hode Y, Nedelec JF, Laine E, Wagner G, Macher JP. 2000. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine. Neuropsychopharmacology 23:428-438.
25. Borys DJ, Setzer SC, Ling LJ, Reisdorf JJ, Day LC, Krenzelok EP. 1992. Acute fluoxetine overdose: a report of 234 cases. Am J Emerg Med 10:115-120.
26. Boulenger A, Viseux V, Plantin-Eon I, Redon JY, Commegeille P, Plantin P. 2003. Gynaecomastia following treatment by fluoxetine. J Eur Acad Dermatol Venereol 17:109.
27. Bourdeaux R, Desor D, Lehr PR, Younos C, Capolaghi B. 1998. Effects of fluoxetine and norfluoxetine on 5-hydroxytryptamine metabolism in blood platelets and brain after administration to rats. J Pharm Pharmacol 50:1387-1392.
28. Boyd GR, Reemtsma H, Grimm DA, Mitra S. 2003. Pharmaceuticals and personal care products (PPCPs) in surface and treated waters of Louisiana, USA and Ontario, Canada. Sci Total Environ 311:135-149.
29. Brandes LJ, Arron RJ, Bogdanovic RP, Tong J, Zaborniak CL, Hogg GR, Warrington RC, Fang W, La Bella FS. 1992. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res 52:3796-3800.
30. Brent NB, Wisner KL. 1998. Fluoxetine and carbamazepine concentrations in a nursing mother/infant pair. Clin pediatr 37:41-44.
31. Brooks BW, Chambliss CK, Johnson RD, Lewis RJ. 2003a. Select pharmaceutical accumulation in teleost liver, brain, and muscle. Geological Society of America Annual Meeting, Seattle: WA.
32. Brooks BW, Foran CM, Richards SM, Weston J, Turner PK, Stanley JK, Solomon KR, Slattery M, La Point TW. 2003b. Aquatic ecotoxicology of fluoxetine. Toxicol Lett 142:169-183.
33. Brosen K, Skjelbo E. 1991. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6 - the source of the sparteine/debrisoquine oxidation polymorphism. Br J Clin Pharmacol 32:136-137.
34. Brunel P, Vial T, Roche I, Bertolotti E, Evreux JC. 1994. First trimester exposure to antidepressant drugs. Result of a follow-up. Therapie 49:117-122.
35. Budavari S. 2001. The Merck Index: an encyclopedia of chemicals, drugs, and biologicals. 13 Ed. Whitehouse Station, NJ: Merck & Co., Inc.
36. Burch KJ, Wells BG. 1992. Fluoxetine/norfluoxetine concentrations in human milk. Pediatrics 89:676-677.
37. Busch L, Wald M, Borda E. 2000a. Influence of castration on the response of the rat vas deferens to fluoxetine. Pharmacol Res 42:305-311.
38. Busch L, Wald M, Sterin-Borda L, Borda E. 2000b. Fluoxetine modulates norepinephrine contractile effect on rat vas deferens. Pharmacol Res 41:39-45.
39. Byrd R, Markham J. 1994. Developmental toxicology studies of fluoxetine hydrochloride administered orally to rats and rabbits. Fund Appl Toxicol 22:511-518.
40. Cabrera TM, Battaglia G. 1994. Delayed decreases in brain 5-hydroxytryptamine2A/2C receptor density and function in male rat progeny following prenatal fluoxetine. J Pharmacol Exp Ther 269:637-645.
41. Cabrera-Vera TM, Battaglia G. 1998. Prenatal exposure to fluoxetine (Prozac) produces site-specific and age-dependent alterations in brain serotonin transporters in rat progeny: evidence from autoradiographic studies. J Pharmacol Exp Ther 286:1474-1481.
42. Cabrera-Vera TM, Garcia F, Pinto W, Battaglia G. 1997. Effect of prenatal fluoxetine (Prozac) exposure on brain serotonin neurons in prepubescent and adult male rat offspring. J Pharmacol Exp Ther 280:138-145.
43. Caccia S. 1998. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 34:281-302.
44. Caccia S, Cappi M, Fracasso C, Garattini S. 1990. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology 100:509-514.
45. Cantor JM, Binik YM, Pfaus JG. 1999. Chronic fluoxetine inhibits sexual behavior in the male rat: reversal with oxytocin. Psychopharmacology 144:355-362.
46. Chambers C, Hernandez-Diaz S, Jones KL, Mitchell AA. 2003. Selective serotonin reuptake inhibitor use during pregnancy and preterm delivery. Pharmacoepidemiology and Drug Safety 12:S1.
47. Chambers C, Johnson K, Jones K. 1993. Pregnancy outcome in females exposed to fluoxetine. Teratology 47:386.
48. Chambers CD, Anderson PO, Thomas RG, Dick LM, Felix RJ, Johnson KA, Jones KL. 1999. Weight gain in infants breast-fed by mothers who take fluoxetine. Pediatrics 104:e61.
49. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. 1996. Birth outcomes in pregnant females taking fluoxetine. N Engl J Med 335:1010-1015.
50. ChemIDplus. 2003. Fluoxetine. Division of Specialized Information Services, NLM.
51. Chouinard G, Saxena B, Belanger MC, Ravindran A, Bakish D, Beauclair L, Morris P, Vasavan Nair NP, Manchanda R, Reesal R, Remick R, O'Neill MC. 1999. A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. J Affect Disord 54:39-48.
52. Clarke AS, Ebert MH, Schmidt DE, McKinney WT, Kraemer GW. 1999. Biogenic amine activity in response to fluoxetine and desipramine in differentially reared rhesus monkeys. Biol Psychiatry 46:221-228.
53. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, Bass KI, Donahue RM, Jamerson BD, Metz A. 2002. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 63:357-366.
54. Clayton AH, Zajecka J, Ferguson JM, Filipiak-Reisner JK, Brown MT, Schwartz GE. 2003. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. Int Clin Psychopharmacol 18:151-156.
55. Cohen LS, Heller VL, Bailey JW, Crush L, Ablon JS, Bouffard SM. 2000. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 48:996-1000.
56. Coleman C, King B, Bolden-Watson C, Book M, Segraves R, Richard N, Ascher J, Batey S, Jamerson B, Metz A. 2001. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 23:1040-1058.
57. Coplan JD, Papp LA, Martinez J, Pine D, Rosenblum LA, Cooper T, Liebowitz MR, Gorman JM. 1995. Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder. Am J Psychiatry 152:619-622.
58. Correa H, Duval F, Claude MM, Bailey P, Tremeau F, Diep TS, Crocq MA, Castro JO, Macher JP. 2001. Noradrenergic dysfunction and antidepressant treatment response. Eur Neuropsychopharmacol 11:163-168.
59. Daniel WA, Haduch A, Wojcikowski J. 2002. Inhibition and possible induction of rat CYP2D after short- and long-term treatment with antidepressants. J Pharm Pharmacol 54:1545-1552.
60. da-Silva VA, Altenburg SP, Malheiros LR, Thomaz TG, Lindsey CJ. 1999. Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy. Braz J Med Biol Res 32:93-98.
61. Del Rio J, Montera D, De Ceballos ML. 1988. Long-lasting changes after perinatal exposure to antidepressants. Prog Brain Res 73:173-187.
62. DeVane CL. 1994. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry 55(Suppl):38-45; discussion 46-37.
63. DeVane CL, Sallee FR. 1996. Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience. J Clin Psychiatry 57:55-66.
64. Dow-Edwards DL. 1996. Modification of acoustic startle reactivity by cocaine administration during the postnatal period: Comparison with a specific serotonin reuptake inhibitor. Neurotoxicol Teratol 18:289-296.
65. Duncan GE, Knapp DJ, Carson SW, Breese GR. 1998. Differential effects of chronic antidepressant treatment on swim stress- and fluoxetine-induced secretion of corticosterone and progesterone. J Pharmacol Exp Ther 285:579-587.
66. Egberts A, Meyboom R, De Koning F, Bakker A, Leufkens H. 1997. Non-puerperal lactation associated with antidepressant drug use. Br J Clin Pharmacol 44:277-281.
67. Elmore JL, Quattlebaum JT. 1997. Female sexual stimulation during antidepressant treatment. Pharmacotherapy 17:612-616.
68. Emslie G, Judge R. 2000. Tricyclic antidepressants and selective serotonin reuptake inhibitors: use during pregnancy, in children/adolescents and in the elderly. Acta Psychiatr Scand Suppl 403:26-34.
69. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, Nilsson M, Jacobson JG. 2002. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 41:1205-1215.
70. Ericson A, Kallen B, Wiholm B. 1999. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 55:503-508.
71. Fairbanks J, Pine D, Tancer N, Dummit E, Kentgen L, Martin J, Asche B, Klein R. 1997. Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. J Child Adolesc Psychopharmacol 7:17-29.
72. Fava M, Amsterdam JD, Deltito JA, Salzman C, Schwaller M, Dunner DL. 1998. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Ann Clin Psychiatry 10:145-150.
73. Food and Drug Administration. 1984. Pharmacologist Review of NDA 18-936. Food and Drug Administration.
74. Food and Drug Administration. 1999. Clinical pharmacology and biopharmaceutics review for Prozac®: Food and Drug Administration Center for Drug Evaluation and Research: NDA 20-974. Report nr 020974.
75. Food and Drug Administration. 2001a. Medical Review for fluoxetine hydrochloride (Prozac®): NDA18-936/SE5-064. Food and Drug Administration Center for Drug Evaluation and Research. Report nr NDA 18-936 SE5-064.
76. Food and Drug Administration. 2001b. OPDRA Postmarketing Safety Review: neonatal withdrawal syndrome: OPDRA PID D010310. Food and Drug Administration. Report nr OPDRA PID DO10310.
77. Food and Drug Administration. 2003a. Clinical Pharmacology and Biopharmaceutics Review for Prozac®. Food and Drug Administration Center for Drug Evaluation and Research: NDA 18-936/SE-064. Report nr NDA 18-936 SE5-064.
78. Food and Drug Administration. 2003b. Federal Drug Administration Talk Paper: Federal Drug Administration approves Prozac for pediatric use to treat depression and OCD. Available at http://www.fda.gov/ bbs/topics/ANSWERS/2003/ ANS01187.html. Food and Drug Administration.
79. Food and Drug Administration. 2003b. Postmarketing reports of adverse reproductive outcomes with fluoxetine. Drug: Fluoxetine hydrochloride (Prozac), NDA 18-936. Rockville, MD: Food and Drug Administration Center for Drug Evaluation and Research.
80. Food and Drug Administration. 2003c. Public Health Advisory: Reports of suicidality in pediatric patients being treated with antidepressant medications for major depressive disorder (MDD). Available at (http://www.fda.gov/cder/drug/ advisory/mdd.htm). Food and Drug Administration.
81. Food and Drug Administration. 2003d. Sales and use of fluoxetine in children, adolescents, and females of child-bearing age for The National Toxicology Program (NTP) Center for the Evaluation of Risks to Human Reproduction (CERHR) Expert Panel 2004. Rockville, MD: Food and Drug Administration Division of Surveillance, Research, and Communication Support, Office of Drug Safety.
82. Food and Drug Administration. 2004. Federal Drug Administration issues public health advisory on cautions for use of antidepressants in adults and children. Available at http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01283.html. Food and Drug Administration.
83. Feierabend RH Jr. 1995. Benign course in a child with a massive fluoxetine overdose. J Fam Pract 41:289-291.
84. Feighner J, Gardner E, Johnston J, Batey S, Moise A, Ascher J, Lineberry C. 1991. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry 52:329-335.
85. Ficicioglu C, Tekin HI, Arioglu PF, Okar I. 1996. Effects of fluoxetine-induced hyperprolactinaemia on adenomyosis induction in Wistar Albino rats. Med Sci Res 24:557-559.
86. Forster P, King J. 1994. Fluoxetine for premature ejaculation: letter. Am J Psychiatry 151:1523.
87. Frackiewicz EJ, Sramek JJ, Cutler NR. 2000. Gender differences in depression and antidepressant pharmacokinetics and adverse events. Ann Pharmacother 34:80-88.
88. Frank GR, Navon RE. 1999. Growth failure associated with the use of high dose Prozac (fluoxetine hydrochloride) in a patient with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 12:467-469.
89. Frye CA, Rhodes ME. 2003. Zaprinast, a phosphodiesterase 5 inhibitor, overcomes sexual dysfunction produced by fluoxetine, a selective serotonin reuptake inhibitor in hamsters. Neuropsychopharmacology 28:310-316.
90. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS. 1999. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 9:669-682.
91. Garcia Campayo J, Sanz Carillo C, Lobo A. 1995. Orgasmic sexual experiences as side-effect of fluoxetine: a case report. Acta Psychiatr Scand 91:69-70.
92. Geller DA, Hoog SL, Heiligenstein JH, Ricardi RK, Tamura R, Kluszynski S, Jacobson JG. 2001. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry 40:773-779.
93. Go FS, Malley EE, Birmaher B, Rosenberg DR. 1998. Manic behaviors associated with fluoxetine in three 12- to 18-year-olds with obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 8:73-80.
94. Goeringer KE, Raymon L, Christian GD, Logan BK. 2000. Postmortem forensic toxicology of selective serotonin reuptake inhibitors: a review of pharmacology and report of 168 cases. J Forensic Sci 45:633-648.
95. Goldstein BJ, Goodnick PJ. 1998. Selective serotonin reuptake inhibitors in the treatment of affective disorders-III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 12(Suppl):S35-87.
96. Goldstein D. 1990. Outcome of fluoxetine-exposed pregnancies. Am J Hum Genet 47:A136.
97. Goldstein D, Williams M, Pearson D. 1991. Fluoxetine-exposed pregnancies. Clin Res 39:768A.
98. Goldstein DJ. 1995. Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol 15:417-420.
99. Goldstein DJ, Corbin LA, Sundell KL. 1997. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 89:713-718.
100. Goldstein DJ, Marvel DE. 1993. Psychotropic medications during pregnancy: risk to the fetus. JAMA 270:2177; discussion 2178.
101. Gould E, Tanapat P, McEwen BS, Flugge G, Fuchs E. 1998. Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress. Proc Natl Acad Sci USA 95:3168-3171.
102. Grimsley SR, Jann MW. 1992. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharmacokinet 11:930-957.
103. Haddad PM. 2001. Antidepressant discontinuation syndromes: clinical relevance, prevention and management. Drug Saf 24:183-197.
104. Haensel SM, Klem TM, Hop WC, Slob AK. 1998. Fluoxetine and premature ejaculation: a double-blind, crossover, placebo-controlled study. J Clin Psychopharmacol 18:72-77.
105. Hale TW, Shum S, Grossberg M. 2001. Fluoxetine toxicity in a breast-fed infant. Clin Pediatr 40:681-684.
106. Hamelin B, Turgeon J, Vallee F, Belanger P, Paquet F, LeBel M. 1996. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 60:512-521.
107. Hansson SR, Mezey E, Hoffman BJ. 1999. Serotonin transporter messenger RNA expression in neural crest-derived structures and sensory pathways of the developing rat embryo. Neuroscience 89:243-265.
108. Harvey AT, Preskorn SH. 2001. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. J Clin Psychopharmacol 21:161-166.
109. Heikkinen T, Ekblad U, Palo P, Laine K. 2003. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 73:330-337.
110. Hendrick V, Smith LM, Suri R, Hwang S, Haynes D, Altshuler L. 2003. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 188:812-815.
111. Hendrick V, Stowe ZN, Altshuler LL, Mintz J, Hwang S, Hostetter A, Suri R, Leight K, Fukuchi A. 2001. Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk. Biol Psychiatry 50:775-782.
112. Herman JB, Brotman AW, Pollack MH, Falk WE, Biederman J, Rosenbaum JF. 1990. Fluoxerine-induced sexual dysfunction. J Clin Psychiatry 51:25-27.
113. Hostetter A, Stowe ZN, Strader JR Jr, McLaughlin E, Llewellyn A. 2000. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety 11:51-57.
114. Hoyt J, Byrd R, Brophy G, Markham J. 1989. A reproduction study of fluoxetine hydrochloride (I) administered in the diet to rats. Teratology 39:459.
115. Hazardous Substances Data Bank. 2003. Fluoxetine. Available at http:// toxnet.nlm.nih.gov/cgi-bin/sis/search/f?./temp/~8nWvMB:1.: National Library of Medicine.
116. Hsieh JT, Chang HC, Law HS, Hsieh CH, Cheng JT. 1998. In vivo evaluation of serotonergic agents and alpha-adrenergic blockers on premature ejaculation by inhibiting the seminal vesicle pressure response to electrical nerve stimulation. Br J Urol 82:237-240.
117. Hsu JH, Shen WW. 1995. Male sexual side effects associated with antidepressants: a descriptive clinical study of 32 patients. Int J Psychiatry Med 25:191-201.
118. Iancu I, Ratzoni G, Weitzman A, Apter A. 1992. More fluoxetine experience. J Am Acad Child Adolesc Psychiatry 31:755-756.
119. Isenberg KE. 1990. Excretion of fluoxetine in human breast milk. J Clin Psychiatry 51:169.
120. Jacobsen FM. 1992. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 53:119-122.
121. Jannuzzi G, Gatti G, Magni P, Spina E, Pacifici R, Zuccaro P, Torta R, Guarneri L, Perucca E. 2002. Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response. Ther Drug Monit 24:616-627.
122. Kafka MP. 1991a. Successful antidepressant treatment of nonparaphilic sexual addictions and paraphilias in men. J Clin Psychiatry 52:60-65.
123. Kafka MP. 1991b. Successful treatment of paraphilic coercive disorder (a rapist) with fluoxetine hydrochloride. Br J Psychiatry 158:844-847.
124. Kafka MP, Prentky R. 1992. Fluoxetine treatment of nonparaphilic sexual addictions and paraphilias in men. J Clin Psychiatry 53:351-358.
125. Kaplan PM. 1994. The use of serotonergic uptake inhibitors in the treatment of premature ejaculation. J Sex Marital Ther 20:321-324.
126. Kara H, Aydin S, Yucel M, Agargun MY, Odabas O, Yilmaz Y. 1996. The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. J Urol 156:1631-1632.
127. Kelly JP, Rosenberg L, Palmer JR, Rao RS, Strom BL, Stolley PD, Zauber AG, Shapiro S. 1999. Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am J Epidemiol 150:861-868.
128. Kelly MW, Perry PJ, Holstad SG, Garvey MJ. 1989. Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Ther Drug Monit 11:165-170.
129. Kim J, Riggs KW, Rurak DW. 2004. Stereoselective pharmacokinetics of fluoxetine and norfluoxetine enantiomers in pregnant sheep. Drug Metab Dispos 32:212-221.
130. Kim S, Seo K. 1998. Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. J Urol 159:425-427.
131. Kindler S, Dolberg OT, Cohen H, Hirschmann S, Kotler M. 1997. The treatment of comorbid premature ejaculation and panic disorder with fluoxetine. Clin Neuropharmacol 20:466-471.
132. Kristensen JH, Ilett KF, Hackett LP, Yapp P, Paech M, Begg EJ. 1999. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br J Clin Pharmacol 48:521-527.
133. Labbate LA, Grimes J, Hines A, Oleshansky MA, Arana GW. 1998a. Sexual dysfunction induced by serotonin reuptake antidepressants. J Sex Marital Ther 24:3-12.
134. Labbate LA, Grimes JB, Arana G. 1998b. Serotonin reuptake antidepressant effects on sexual function in patients with anxiety disorders. Biol Psychiatry 43:904-907.
135. Laine K, Heikkinen T, Ekblad U, Kero P. 2003. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 60:720-726.
136. Lauder JM, Tamir H, Sadler TW. 1988. Serotonin and morphogenesis. I. Sites of serotonin uptake and -binding protein immunoreactivity in the midgestation mouse embryo. Development 102:709-720.
137. Lawlor DA, Juni P, Ebrahim S, Egger M. 2003. Systematic review of the epidemiologic and trial evidence of an association between antidepressant medication and breast cancer. J Clin Epidemiol 56:155-163.
138. Lee HS, Song DH, Kim CH, Choi HK. 1996. An open clinical trial of fluoxetine in the treatment of premature ejaculation. J Clin Psychopharmacol 16:379-382.
139. Lester BM, Cucca J, Andreozzi L, Flanagan P, Oh W. 1993. Possible association between fluoxetine hydrochloride and colic in an infant. J Am Acad Child Adolesc Psychiatry 32:1253-1255.
140. Lilly. 2002a. Annual Report 2001. Indianapolis, IN: Eli Lilly and Company.
141. Lilly. 2002b. Sarafem™ fluoxetine hydrochloride product labeling. Indianapolis, IN: Eli Lilly and Company. 23 p.
142. Lilly. 2003. Prozac® fluoxetine hydrochloride product labeling. Indianapolis, IN: Eli Lilly and Company. 26 p.
143. Liu ZQ, Cheng ZN, Huang SL, Chen XP, Ou-Yang DS, Jiang CH, Zhou HH. 2001. Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. Br J Clin Pharmacol 52:96-99.
144. Lydiard R, George M. 1989. Fluoxetine-related anorgasmy. South Med J 82:933-934.
145. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. 2000. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20:9104-9110.
146. Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, Obach RS. 2000. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos 28:1187-1191.
147. Mattson SN, Eastvold AD, Jones KL, Harris JA, Chambers CD. 1999. Neurobehavioral follow-up of children prenatally exposed to fluoxetine. Teratology 59:376.
148. Matuszczyk JV, Larsson K, Eriksson E. 1998a. The selective serotonin reuptake inhibitor fluoxetine reduces sexual motivation in male rats. Pharmacol Biochem Behav 60:527-532.
149. Matuszczyk JV, Larsson K, Eriksson E. 1998b. Subchronic administration of fluoxetine impairs estrous behavior in intact female rats. Neuropsychopharmacology 19:492-498.
150. McElhatton PR, Garbis HM, Elefant E, Vial T, Bellemin B, Mastroiacovo P, Arnon J, Rodriguez-Pinilla E, Schaefer C, Pexieder T, Merlob P, Dal Verme S. 1996. The outcome of pregnancy in 689 females exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 10:285-294.
151. Medina P, Segarra G, Ballester R, Chuan P, Domenech C, Vila JM, Lluch S. 2000. Effects of antidepressants in adrenergic neurotransmission of human vas deferens. Urology 55:592-597.
152. Mendes-da-Silva C, de Souza SL, Barreto-Medeiros JM, de Freitas-Silva SR, Antunes DE, Cunha AD, Ribas VR, de Franca MF, Nogueira MI, Manhaes-de-Castro R. 2002. Neonatal treatment with fluoxetine reduces depressive behavior induced by forced swim in adult rats. Arq Neuropsiquiatr 60:928-931.
153. Menkes DB, Taghavi E, Mason PA, Howard RC. 1993. Fluoxetine's spectrum of action in premenstrual syndrome. Int Clin Psychopharmacol 8:95-102.
154. Mhanna MJ, Bennet JB 2nd, Izatt SD. 1997. Potential fluoxetine chloride (Prozac) toxicity in a newborn. Pediatrics 100:158-159.
155. Michelson D, Schmidt M, Lee J, Tepner R. 2001. Changes in sexual function during acute and six-month fluoxetine therapy: a prospective assessment. J Sex Marital Ther 27:289-302.
156. Modell J. 1989. Repeated observations of yawning, clitoral engorgement and orgasm associated with fluoxetine administration (letter). J Clin Psychopharmacol 9:63-65.
157. Modell JG, Katholi CR, Modell JD, DePalma RL. 1997. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther 61:476-487.
158. Mohan CG, Moore JJ. 2000. Fluoxetine toxicity in a preterm infant. J Perinatol 20:445-446.
159. Moiseiwitsch J, Lauder J. 1996. Stimulation of murine tooth development in organotypic culture by the neurotransmitter serotonin. Arch Oral Biol 41:161-165.
160. Moiseiwitsch JR, Raymond JR, Tamir H, Lauder JM. 1998. Regulation by serotonin of tooth-germ morphogenesis and gene expression in mouse mandibular expiant cultures. Arch Oral Biol 43:789-800.
161. Montejo A, Llorca G, Izquierdo J, Rico-Villademoros F. 2001. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. Clin Psychiatry 62(Suppl):10-21.
162. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, Ledesma A, Bousono M, Calcedo A, Carrasco JL, Ciudad J, Daniel E, De la Gandara J, Derecho J, Franco M, Gomez MJ, Macias JA, Martin T, Ferez V, Sanchez JM, Sanchez S, Vicens E. 1997. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 23:176-194.
163. Montera D, de Ceballos M, Del Rio J. 1990. Down-regulation of 3H-imipramine binding sites in rat cerebral cortex after prenatal exposure to antidepressants. Life Sci 46:1619-1626.
164. Morrell DJ, Countryman RA, Morgan RE. 2001. Enduring effects of pre-and postnatal fluoxetine exposure on sustained and selective attention. Neurotoxicol Teratol 23:289.
165. Morrison JL, Chien C, Gruber N, Rurak D, Riggs W. 2001. Fetal behavioural state changes following maternal fluoxetine infusion in sheep. Brain Res Dev Brain Res 131:47-56.
166. Morrison JL, Chien C, Riggs KW, Gruber N, Rurak D. 2002. Effect of maternal fluoxetine administration on uterine blood flow, fetal blood gas status, and growth. Pediatr Res 51:433-442.
167. Mos J, Mollet I, Tolboom JT, Waldinger MD, Olivier B. 1999. A comparison of the effects of different serotonin reuptake blockers on sexual behaviour of the male rat. Eur Neuropsychopharmacol 9:123-135.
168. Murphy TK, Bengtson MA, Tan JY, Carbonell E, Levin GM. 2000. Selective serotonin reuptake inhibitors in the treatment of paediatric anxiety disorders: a review. Int Clin Psychopharmacol 15(Suppl):S47-63.
169. Murray MJ, Hooberman D, 1993. Fluoxetine and prolonged erection. Am J Psychiatry 150:167-168.
170. Musher J. 1990. Anorgasmia with the use of fluoxetine. Am J Psychiatry 147:948.
171. Nguyen TT, Tseng YT, McGonnigal B, Stabila JP, Worrell LA, Saha S, Padbury JF. 1999. Placental biogenic amine transporters: in vivo function, regulation and pathobiological significance. Placenta 20:3-11.
172. Nordeng H, Lindemann R, Perminov KV, Reikvam A. 2001. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 90:288-291.
173. Norrholm SD, Ouimet CC. 2000. Chronic fluoxetine administration to juvenile rats prevents age-associated dendritic spine proliferation in hippocampus. Brain Res 883:205-215.
174. Nulman I, Rovet J, Stewart D, Kulin NA, Koren G. 1996. Neurodevelopment of children exposed to fluoxetine in utero: a prospective longitudinal study. Clin Pharmacol Ther 59:159.
175. Nulman I, Rovet J, Siewart DE, Wolpin J, Gardner HA, Theis JG, Kulin N, Koren G. 1997. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 336:258-262.
176. Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, Koren G. 2002. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 159:1889-1895.
177. Oberlander TF, Eckstein Grunau R, Fitzgerald C, Ellwood AL, Misri S, Rurak D, Riggs KW. 2002. Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res 51:443-453.
178. O'Flynn K, O'Keane V, Lucey J, Dinan T. 1991. Effect of fluoxetine on noradrenergic mediated growth hormone release: a double blind, placebo-controlled study. Biol Psychiatry 30:377-382.
179. Ozeren S, Corakci A, Yucesoy I, Mercan R, Erhan G. 1997. Fluoxetine in the treatment of premenstrual syndrome. Eur J Obstet Gynecol Reprod Biol 73:167-170.
180. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, Donnenfeld A, McCormack M, Leen-Mitchell M, Woodland C, et al. 1993. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 269:2246-2248.
181. Patterson W. 1993. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 54:71.
182. Pearlstein TB, Stone AB. 1994. Long-term fluoxetine treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 55:332-335.
183. Pecins-Thompson M, Bethea CL. 1997. RU 486 blocks and fluoxetine augments progesterone-induced prolactin secretion in monkeys. Neuroendocrinology 65:335-343.
184. Pennisi G, Attaguile G, Chillemi L, Leanza R. 1999. Effects of in utero
185. Perilstein RD, Lipper S, Friedman LJ. 1991. Three cases of paraphilias responsive to fluoxetine treatment. J Clin Psychiatry 52:169-170.
186. Perlis RH, Mischoulon D, Smoller JW, Wan YJ, Lamon-Fava S, Lin KM, Rosenbaum JF, Fava M. 2003. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 54:879-883.
187. Pinilla L, Gonzalez LC, Tena-Sempere M, Aguilar E. 2001. 5-HT1 and 5-HT2 receptor agonists blunt ±-alpha-amino-S-hydroxy-S-methylisoxazole-4- propionic acid (AMPA)-stimulated GH secretion in prepubertal male rats. Eur J Endocrinol 144:535-541.
188. Pohland RC, Byrd TK, Hamilton M, Koons JR. 1989. Placental transfer and fetal distribution of fluoxetine in the rat. Toxicol Appl Pharmacol 98:198-205.
189. Power Smith P. 1994. Beneficial sexual side-effects from fluoxetine. Br J Psychiatry 164:249-250.
190. Raap DK, Van de Kar LD. 1999. Mini review: Selective serotonin reuptake inhibitors and neuroendocrine function. Life Sci 65:1217-1235.
191. Rausch JL, Johnson ME, Fei Y, Li JQ, Shendarkar N, Mac Hobby H, Ganapathy V, Leibach FH. 2002. Initial conditions of serotonin transporter kinetics and genotype: Influence on SSRI treatment trial outcome. Biol Psychiatry 51:723-732.
192. Riddle MA, Hardin MT, King R, Scahill L, Woolston JL. 1990. Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 29:45-48.
193. Romero G, Toscano E, Del Rio J. 1994. Effect of prenatal exposure to antidepressants on 5-HT-stimulated phosphoinositide hydrolysis and 5-HT2 receptors in rat brain. Gen Pharmacol 25:851-856.
194. Rosa F. 1994. Medicaid antidepressant pregnancy exposure outcomes. Reprod Toxicol 8:444.
195. Rudolph M, Oviedo C, Vega E, Martinez L, Reinicke K, Villar M, Villan L. 1998. Oxytocin inhibits the uptake of serotonin into uterine mast cells. J Pharmacol Exp Ther 287:389-394.
196. Sallee FR, DeVane CL, Ferrell RE. 2000. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J Child Adolesc Psychopharmacol 10:27-34.
197. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R. 2003. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301:805-809.
198. Scahill L, Riddle MA, King RA, Hardin MT, Rasmusson A, Makuch RW, Leckman JF. 1997. Fluoxetine has no marked effect on tic symptoms in patients with Tourette's syndrome: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 7:75-85.
199. Seo KK, Kim SC, Lee MY. 2001. Comparison of peripheral inhibitory effects of clomipramine with selective serotonin re-uptake inhibitors on contraction of vas deferens: in vitro and in vivo studies. J Urol 165:2110-2114.
200. Sheline YI, Gado MH, Kraemer HC. 2003. Untreated depression and hippocampal volume loss. Am J Psychiatry 160:1516-1518.
201. Shen W, Hsu J. 1995. Female sexual side effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients. Int J Psychiatry Med 25:239-248.
202. Shuey D, Sadler T, Lauder J. 1992. Serotonin as a regulator of craniofacial morphogenesis: site specific malformations following exposure to serotonin uptake inhibitors. Teratology 46:367-378.
203. Simon GE, Cunningham ML, Davis RL. 2002. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 159:2055-2061.
204. Singh Y, Jaiswal A, Singh M, Bhattacharya S. 1998. Effect of prenatal diazepam, phenobarbital, haloperidol and fluoxetine exposure on foot shock induced aggression in rats. Indian J Exp Biol 36:1023-1024.
205. Smith D, Levitte S. 1993. Association of fluoxetine and return of sexual function in three elderly men. J Clin Psychiatry 54:317-319.
206. Spencer M. 1993. Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics 92:721-722.
207. Stanford M, Patton J. 1993. In utero exposure to fluoxetine HCl increases hematoma frequency at birth. Pharmacol Biochem Behav 45:959-962.
208. Steiner M, Lamont J, Steinberg S, Stewart D, Reid R, Streiner D. 1997. Effect of fluoxetine on menstrual cycle length in females with premenstrual dysphoria. Obstet Gynecol 90:590-595.
209. Stewart C, Scalzo F, Valentine J, Holson R, Ali S, Slikker W. 1998. Gestational exposure to cocaine or pharmacologically related compounds: effects on behavior and striatal dopamine receptors. Life Sci 63:2015-2022.
210. Stokes AP, Holtz A. 1997. Fluoxetine tenth anniversary update: the progress continues. Clin Ther 19:1135-1250.
211. Strain SL. 1994. Fluoxetine-initiated ovulatory cycles in two clomiphene-resistant females. Am J Psychiatry 151(4):620.
212. Sullivan SD, Howard LC, Clayton AH, Moenter SM. 2002. Serotonergic activation rescues reproductive function in fasted mice: does serotonin mediate the metabolic effects of leptin on reproduction? Biol Reprod 66:1702-1706.
213. Suri R, Stowe ZN, Hendrick V, Hostetter A, Widawski M, Altshuler LL. 2002. Estimates of nursing infant daily dose of fluoxetine through breast milk. Biol Psychiatry 52:446-451.
214. Swenson JR. 1993. Fluoxetine and sexual dysfunction. Can J Psychiatry 38:297.
215. Tabacova S. 2001. Fluoxetine developmental toxicity: animal-to-human comparisons. Food and Drug Administration National Center for Toxicological Research.
216. Taddio A, Ito S, Koren G. 1996. Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk. J Clin Pharmacol 36:42-47.
217. Taylor G, Bardgett M, Csernansky J, Early T, Haller J, Scherrer J, Womack S. 1996. Male reproductive systems under chronic fluoxetine or trimipramine treatment. Physiol Behav 59:479-485.
218. Thakore JH, Dinan TG. 1995. Effect of fluoxetine on dexamethasone-induced growth hormone release in depression: a double-blind, placebo-controlled study. Am J Psychiatry 152:616-618.
219. Tutton P, Barkla D. 1982. Influence of inhibitors of serotonin uptake on intestinal epithelium and colorectal carcinomas. Br J Cancer 46:260-265.
220. Urban R, Veldhuis J. 1990. Effect of short-term stimulation of serotoninergic pathways on the pulsatile secretion of luteinizing hormone in the absence and presence of acute opiate-receptor blockage. J Androl 11:227-232.
221. Urban RJ, Veldhuis JD. 1991. A selective serotonin reuptake inhibitor, fluoxetine hydrochloride, modulates the pulsatile release of prolactin in postmenopausal females. Am J Obstet Gynecol 164:147-152.
222. Van de Kar LD, Raap DK, Battaglia G, Muma NA, Garcia F, Don Carlos LL. 2002. Treatment of cycling female rats with fluoxetine induces desensitization of hypothalamic 5-HT(1A) receptors with no change in 5-HT(2A) receptors. Neuropharmacology 43:45-54.
223. Vedernikov Y, Bolanos S, Bytautiene E, Fulep E, Saade G, Garfield R. 2000. Effect of fluoxetine on contractile activity of pregnant rat uterine rings. Am J Obstet Gynecol 182:296-299.
224. Vendittelli F, Alain J, Nouaille Y, Brosset A, Tabaste JL. 1995. A case of lipomeningocele reported with fluoxetine (and alprazolam, vitamins B1 and B6, heptaminol) prescribed during pregnancy. Eur J Obstet Gynecol Reprod Biol 58:85-86.
225. Vitek R. 2000. Lessons from Lilly's Prozac patent case. Triangle Business Journal.
226. Vitiello B, Jensen PS. 1995. Developmental perspectives in pediatric psychopharmacology. Psychopharmacol Bull 31:75-81.
227. Vorhees C, Acuff-Smith K, Schilling M, Fisher J, Moran M, Buelke-Sam J. 1994. A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam Appl Toxicol 23:194-205.
228. Warnock JK, Clayton AH, Shaw HA, O'Donnell T. 1995. Onset of menses in two adult patients with Prader-Willi syndrome treated with fluoxetine. Psychopharmacol Bull 31:239-242.
229. Wegerer V, Moll GH, Bagli M, Rothenberger A, Ruther E, Huether G. 1999. Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life. J Child Adolesc Psychopharmacol 9:13-24; discussion 25-16.
230. Weintrob N, Cohen D, Klipper-Aurbach Y, Zadik Z, Dickerman Z. 2002. Decreased growth during therapy with selective serotonin reuptake inhibitors. Arch Pediatr Adolesc Med 156:696-701.
231. Wilton L, Pearce G, Martin R, Mackay FJ, Mann R. 1998. The outcomes of pregnancy in females exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 105:882-889.
232. Wong DT, Bymaster FP, Engleman EA. 1995. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 57:411-441.
233. Wu J, Viguera A, Riley L, Cohen L, Ecker J. 2002. Mood disturbance in pregnancy and the mode of delivery. Am J Obstet Gynecol 187:864-867.
234. Yavarone M, Shuey D, Tamir H, Sadler T, Lauder J. 1993. Serotonin and cardiac morphogenesis in the mouse embryo. Teratology 47:573-584.
235. Yells DP, Prendergast MA, Hendricks SE, Nakamura M. 1994. Fluoxetine-induced inhibition of male rat copulatory behavior: modification by lesions of the nucleus paragigantocellularis. Pharmacol Biochem Behav 49:121-127.
236. Yilmaz U, Tatlisen A, Turan H, Arman F, Ekmekcioglu O. 1999. The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation. J Urol 161:107-111.
237. Yoshida K, Smith, Craggs M, Kumar R. 1998. Fluoxetine in breast-milk and developmental outcome of breast-fed infants. Br J Psychiatry 172:175-179.
238. Zajecka J, Fawcett J, Schaff M, Jeffriess H, Guy C. 1991. The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry 52:66-68.
239. Zajecka J, Mitchell S, Fawcett J. 1997. Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the rush sexual inventory. Psychopharmacol Bull 33:755-760.
240. Zeskind PS, Stephens LE. 2004. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 113:368-375.